) million, due to the group gaining profit from exchange rate in 2017 from the imported solar cells for the solar energy business, but no gain in 2018. Selling and administration expenses Selling expenses
. would like to inform the financial results for the second quarter of 2019. The Company and its subsidiary reported a net profit of THB 131. 25 million, comparing to a net profit of THB 126. 43 million in
foreign exchange gain/(loss) (0.30) 1.30 (0.86) 186.67% -166.15% (0.16) (0.36) 125.00% Other income 0.49 0.46 1.54 214.29% 234.78% 1.74 2.81 61.49% Earnings before interest and taxes 16.94 47.20 71.28
investments in associates and JVs /3 Excluding FX impact and one-time gain/(loss) items During 2018, the Company had reported net profit of THB 2,906.8 mm, which decreased by THB 359.6 mm or 11.0%, compared to
sales. Core Net Profit is the Reported Net Profit less extraordinary items less tax adjusted inventory gain/loss. Net Operating Debt is Net Debt (total debt less cash and current investments) less cash
Impairment Loss on Loans and Debt Securities 7,995 7,819 176 2.26 10,626 (2,631) (24.76) Net Profit (attributable to equity holders of KBank) 10,917 10,766 151 1.40 8,986 1,931 21.49 Basic Earnings per Share
companies. (3) Comprises of total revenue net dividend income, gain on foreign exchange, interest income and non-operating revenues. 11 ASIA’S BOUTIQUE AIRLINE Operating Profit and Net Income The operating
) 729.9% Gross profit 426.3 446.0 463.1 3.8% 8.6% 1,200.9 1,337.0 11.3% Net gain (loss) on exchange rate (7.3) (58.6) 37.6 N.A.(>100) N.A.(>100) (83.2) 91.2 N.A.(>100) Gain from business acquisition - - 2.2
% (2,766.3) (3,674.1) 32.8% Gross profit 496.5 463.7 464.1 0.1% (6.5%) 1,401.5 1,399.4 (0.1%) Net gain (loss) on exchange rate 83.6 86.7 113.7 31.1% 36.0% 169.6 195.8 15.4% Gain (loss) on forward contracts 6.0
Company reported net loss attributable to the equity holder of the Company was 338.6 million baht. Loss per share for this quarter was 0.16 baht. Notable Event 1Q2020 Airline Business 1. The COVID-19